Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.77 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL1B | P01584 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794426 | 1.00 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19612031 | 0.94 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19612033 | 0.94 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2381262 | 0.92 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29877286 | 0.91 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24737277 | 0.91 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2381765 | 0.91 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL31618803 | 0.91 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29636257 | 0.91 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL31009046 | 0.91 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | claimed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | claimed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | claimed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022188819-A1 | SOS1 PROTEOLYSIS MODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2022-09-15 | — | — | WO | disclosed |
| CN-115043817-A | SOS1 proteolysis regulator and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3820532-A2 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. Lee Moffitt Cancer Center & Research Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7091353-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | DDB1 1404/4885CRBN 1/4885IKZF3 327/4885 |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | DDB1 3650/4885CRBN 1511/4885IKZF3 2/4885 |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, TNFRSF1A | DDB1 3627/4885CRBN 1695/4885IKZF3 2/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | DDB1 110/4885CRBN 1/4885IKZF3 855/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | DDB1 3650/4885CRBN 1511/4885IKZF3 2/4885 |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | CDK4, CDK6, CDK2 | DDB1 103/4885CRBN 185/4885IKZF3 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.